SPH3643: A novel cyclin‐dependent kinase 4/6 inhibitor with good anticancer efficacy and strong blood‐brain barrier permeability

The cyclin‐dependent kinase (CDK)4/6‐cyclin D1‐Rb‐p16/ink4a pathway is responsible for regulating cell progression past the G(1) restriction point during the cell cycle. The development of a majority of human tumors is associated with dysregulation of this pathway, resulting in increased cancer cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, XueMei, Hong, Yuan, Mao, Yu, Chen, Na, Wang, Qian, Wang, Zhe, Zhang, LeDuo, Wang, Li, Shi, Chen, Shi, WeiJun, Ge, Hui, Li, AnDi, Li, Xin, Xia, GuangXin, Liu, YanJun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226180/
https://www.ncbi.nlm.nih.gov/pubmed/32103527
http://dx.doi.org/10.1111/cas.14367

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226180/
https://www.ncbi.nlm.nih.gov/pubmed/32103527
http://dx.doi.org/10.1111/cas.14367

Ejemplares similares